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Acute bacterial meningitis is an important cause of morbidity and mortality among children
less than five years old. Haemophilus influenzae, Streptococcus pneumoniae and Neisseria
meningitidis are the most important agents of bacterial meningitis in developing countries. The
development of the conjugate vaccines in the beginning of the 90’s, especially type b H. influenzae
(Hib), and more recently the heptavalent pneumococcal and the serogroup C meningococcal vaccines,
have contributed directly to changes in the epidemiological profile of these invasive diseases
(direct effect) and of their carriage status (indirect effect). We review the impact of the Hib
conjugate vaccine in Latin American countries, where this vaccine has been implemented, and the
potential of pneumococcal and meningococcal conjugate vaccines for the reduction of meningitis
worldwide. We also address constraints for the development and delivery of these vaccines and
review new candidate state-of-the-art vaccines. The greatest challenge, undoubtedly, is to implement
these vaccines worldwide, especially in the developing regions.
Key Words: Conjugate vaccines, Hib conjugate vaccine, pneumococcal conjugate vaccine,
meningococcal conjugate vaccine, impact of Hib conjugate vaccine.
Acute bacterial meningitis is an important cause of
morbidity among children, especially in developing
countries [1,2]. Despite the increasing availability of
potent antimicrobials and sophisticated intensive care
units, mortality rates due to bacterial meningitis still
reach high levels, leading to significant neurological
sequelae [3,4].
The advent of the conjugate vaccines during the
last decade was a remarkable achievement,
launching a new era in the history of modern
vaccinology. In contrast to the first generation of the
purified polysaccharide vaccines, the conjugate
vaccines produce a T-dependent response and result
in the development of an immunological memory,
leading to clinical protection in children less than 2
years old [5,6]. This age group is at high risk for
invasive diseases caused by the three most important
agents of bacterial meningitis: Haemophilus
influenzae, Streptococcus pneumoniae  and
Neisseria meningitidis [1].
The development of a conjugate vaccine against type
b H. influenzae (Hib) in the early 1990’s, and its
implementation for routine immunization, have
contributed directly to changes in the epidemiological
profile of the invasive diseases caused by Hib in some
developed countries, especially meningitis [7,8]. More
recently, pneumococcal heptavalent conjugate vaccine
and serogroup C meningococcal conjugate vaccine
were licensed for commercial use, while the 9 to 11
valent pneumococcal vaccines are at an advanced stage
of field trials in many countries [9-13].
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Finland, Canada, Iceland, United States, United
Kingdom, Israel and Australia were the first countries to
use the Hib vaccine on a large scale at the end of the
1980’s and the beginning of the 90’s. Heath, in a review
about the efficacy of Hib vaccine in these countries,
indicated a spectacular reduction of invasive disease
incidence due to H. influenzae b [14]. In the USA, Adams
et al. observed a decrease of 82% in H. influenzae
meningitis between 1985 and 1991 based on national
surveillance data [7]. Dawson et al. [15], in a retrospective
study, detected a fall in the number of meningitis cases by
H. influenzae b, from 73% to 69%, with the
polysaccharide vaccine, and to 16%, within a 5-year-
period after the introduction of the conjugate vaccine.
In Latin America (LA), the conjugate vaccine was
first introduced into Uruguay in 1994, followed by Costa
Rica and Chile, and it is currently incorporated into the
immunization programs of almost all LA countries [16].
In Uruguay, the incidence rate of Hib meningitis fell from
15.6 to 0.03 per 100,000, 2 years after the introduction
of this vaccine [17]. In Brazil, this vaccine was first used
in Curitiba (southern Brazil) in 1996, and after a year of
routine use, a 72% reduction was observed in the
incidence of meningitis [18]. Nationwide immunization
in Brazil began in mid 1999, and after 2 years, Simões
et al. [19], in a prospective population surveillance
carried out in Goiás State (Central Brazil), demonstrated
a 78% decline in the risk of meningitis by H. influenzae
b among children under 5 years of age. Furthermore,
studies conducted in Brasília and Salvador detected a
reduction of meningitis cases of 80% and 69.9%,
respectively, after the first year of the initiation of Hib
vaccination [20,21]. The impact of Hib vaccine on
the reduction of meningitis in Latin America countries
after the introduction of the Hib vaccine in this region
ranged from 40.0% to 95.6%, depending on the time-
period of assessment (Table 1) [18-26].
The significant decline of bacterial meningitis caused
by Hib was due not only to the direct effect of this
vaccine on individual protection, but also to the
reduction of colonization of the nasopharynx [27-31],
decreasing the transmission of Hib and therefore the
incidence of meningitis by H. influenzae b in vaccine
recipients as well as in non-vaccinated children (indirect
effect of the vaccine – herd immunity) [32].
Despite the availability of the Hib conjugate vaccine
and its impressive impact on invasive diseases in
countries where it has been implemented, about 132
million children have not been treated with this vaccine,
most of them in poor countries in Africa and Asia. A
map (Figure 1) shows the current geography of Hib
vaccine implementation in the world [33].
Important obstacles have hampered the introduction
of this vaccine into the African and Asian continents.
Information about the production, the estimated costs,
the use of the vaccine on a large scale, as well as the
safety and efficacy of this vaccine are essential in these
regions. Various investigations have shown cost to be
the most critical issue to introduce the vaccination in
these countries, whereas safety and efficacy, although
significant, are less relevant. The unfavorable economic
and financial situation in many countries in Africa have
impeded increases in per capita spending on health,
making it unfeasible to introduce the Hib vaccine [34].
Most countries in Africa have limited medical and
laboratory support, making the proper identification of
etiological agents involved in invasive diseases difficult.
Moreover, other complex health problems, including
tuberculosis, malaria, HIV and meningococcal disease,
compete against H. influenzae b for priority. The public
health policy makers need to be aware of the magnitude
and the social costs of the Hib diseases, and they should
maximize efforts to incorporate this vaccine into routine
health services [35,36].
Pneumococcal Conjugate Vaccine
In comparison with Hib, Streptococcus pneumoniae
is involved in a broader range of disorders, including
invasive (pneumonia and meningitis), and non-invasive
(acute otitis media and sinusitis) diseases. It also contributes
to the highest levels of mortality and morbidity in the world,
especially in children under 5 years old [37-39]; at least
1.2 million deaths occur annually due to pneumonia, 39%
are children less than 5 years, with 100,000 to 500,000
deaths by pneumococcal meningitis [37].
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Table 1. Impact of Haemophilus influenzae b conjugate vaccine on meningitis in Latin American countries
Country Author, year Vaccine Age group Timing after Hib Coefficients x105 % Decrease
introduction vaccine introduction pre/post vaccine post vaccine
Cuba Dickinson et al. 2001 [23] 1999 < 5 years 1 year 13.6 / 7.6 52.8
Colombia Agudelo et al. 2000 [24] 1998 < 1 year 1 year - 40.0
Uruguay Ruocco et al. 1999 [17] 1994 < 5 years 2 years 15.6 / 2.7 82.7
Landaverde et al.1999 [25] 1994 All ages 6 months - 95.6
Chile Diaz et al. 2001 [26] 1996 < 5 years 2 years 36.4 / 9.9 72.7
Brazil Takemura & 1996 < 5 years 1 year 35.4 / 9.7 72.6
  Andrade 2001 [18]
Freitas 2000 [20] 1999 < 5 years 1 year - 80.0
Simões et al. 2002 [19] 1999 < 5 years 1 year 10.8 / 2.3 78.7
Ribeiro et al. 2003 [21] 1999 < 5 years 1 year 2.6 / 0.8 69.0
Source: Adapted from Simões 2002 [22].
a not reported.
b
 metropolitan area of Santiago.
c incidence in non-exposed to vaccine.
d incidence in exposed to vaccine.
e reference: Wenger et al 2000.
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Figure 1. [33]
The success achieved by Hib immunization has
stimulated the development of a pneumococcal
conjugate vaccine. In February 2000 the Food and
Drug Administration approved the use of a seven-
valent conjugate vaccine for American children under
2 years old. Among the 90 S. pneumoniae serotypes
identified so far [40], the formulation of this vaccine
contains only 7 serotypes – 4, 6B, 9V, 14, 18C, 19F
and 23F, but these are responsible for 70% to 90% of
the invasive disease cases in children in the USA,
Canada, Africa and Europe and are 70% of the
pneumococci that cause acute otitis media in USA,
Canada and Europe [41,42]. Clinical trials carried out
with the 7-valent vaccine in USA have revealed high
levels of protection against invasive pneumococcal
disease, and another review found a 50% to 60%
protection range against serotype specific
pneumococcal otitis  in Finland [43,44]. In Brazil, the
heptavalent vaccine was licensed in February 2001
[45], but it has still not been added to the PNI (national
program of immunizations) schedule. The 9-valent
conjugate vaccine contains the 7-valent serotypes, as
well as serotypes 1 and 5, and it has been evaluated
by large-scale field trials in South Africa and Gambia
[46]. The 11-valent vaccine includes the 9-valent
serotypes, as well as serotypes 3 and 7V, and it is
currently under test in clinical trials in the Philippines,
Israel, Argentina and Chile [13,38,47].
While the expected impact of the Hib conjugate vaccine
is a reduction in meningitis cases, the pneumococcal
vaccines are also expected to reduce pneumonia and acute
otitis media cases, as well as carriage prevalence, which
will significantly modify pneumococcal disease
epidemiology [48-50]. Eskola and Anttila [19] have
shown that in clinical trials with the 7-11 valent
pneumococcal conjugate vaccines, the coverage against
invasive disease, including meningitis, can reach 92%.
DiFabio et al. [51] estimated a 64.4% serotype coverage
(95% confidence interval (CI: 60.7%-67.8%) for
meningitis with the use of the heptavalent pneumococcal
vaccine in Brazil. Similar results were reported by
Brandileone et al. [52], who found that the 7-valent
vaccine would cover 61% (95% CI: 57.0%-64.9%) of
the most prevalent meningitis serotypes in Brazil in children
under 2 years old (1, 14, 19A, 19F, 5, 6A and 6B). It is
worthwhile emphasizing the high prevalence of serotypes
1 and 5 in Latin American countries, which are not included
in the heptavalent vaccine.
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The efficacy of pneumococcal vaccine against
meningitis needs to be better evaluated. So far, clinical
trials conducted in California by the Kaiser group, and
in Navajo children, did not find any case of meningitis
in the vaccinated group; however, as the number of
cases in the control group has not yet been reported
[48,53,54], it is probable that the efficacy of the
heptavalent vaccine against pneumococcal meningitis
would be better evaluated through meta-analyzes, which
have the advantage of pooling to attain a higher sample
size, increasing the power to detect significant
differences between vaccinated and unvaccinated
groups. Observational studies may also be conducted
to assess the effectiveness of the pneumococcal vaccine
during the vaccine post-licensure period.
Although there has been optimism concerning the
impact of the S. pneumoniae conjugate vaccine, there
are some restrictions against its incorporation into health
services routine, including: (i) the high cost for
implementation at a public health level, especially in
the developing world, (ii) controversy about cross-
protection against serotypes not contained in the
vaccine, and (iii) the technical difficulties of having all
pneumococcal serotypes in the same formulation.
Consequently, alternative candidates to the
pneumococcal vaccine have been tested for
immunogenicity and safety, including protein vaccines.
A large number of investigators have searched for
proteins capable of inducing immunity to invasive and
non-invasive pneumococcal infection. Pneumococcal
surface proteins, including protein A (PspA), protein
C (PspC), adhesin (PsaA) and pneumolysin, have been
considered as alternatives to promote protective
immunity in children [55,56]. These proteins can induce
protection regardless of pneumococcal serotype; for
example, PspA has been found in all isolates of S.
pneumoniae [57]. According to the amino acids
sequences, PspA can be classified into three families.
Families 1 and 2 are the main ones, and are found in
more than 98% of the PspA molecules [58,59]. Studies
conducted in animal models have showed that PspA
was the most efficacious protein for immunization
against carriage, otitis media, pneumonia and sepsis. A
synergistic effect has been detected when two proteins
are associated. A combination of PspA and
pneumolysin can induce a higher immunity to lung
infections and probably against septicemia, when
compared to PspA alone [55,60]. The relative
protective capacities of several different pneumococcal
proteins against sepsis, bacteremia, pneumonia, otitis
media and carriage suggest that the association of
different proteins optimizes protection against a broad
variety of strains and diseases. Therefore, it is plausible
that vaccines against S. pneumoniae composed of
mixtures of polysaccharides and several protein
antigens might be a better approach than a vaccine
based on a single type.
Meningococcal Conjugate Vaccine
Meningococcal meningitis is an important public
health problem worldwide, especially in sub-Saharan
Africa, where it occurs as an endemic disease, with
outbreaks every 2 years [61,62]. Neisseria meningitis
isolates can be classified into 12 groups, based on
chemically and antigenically distinct polysaccharide
capsules, but only 5 groups are responsible for almost
all meningococcal disease: A, B, C, Y and W135.
Serogroup A is responsible for epidemic disease in sub-
Saharan Africa and in developing countries in other
regions. Serogroups B and C are responsible for most
of the infections in developed countries, as well as in
developing regions. The pattern of disease caused by
serogroup B is typically hyperendemic or sporadic, in
contrast to the endemic nature of serogroup A. In the
United Kingdom, 32% of the reports of invasive
disease caused by N. meningitidis in 1996 were
associated with serogroup C [6]. Meningococcal
disease caused by serogroups Y and W135 is mainly
found in the USA [62].
The polysaccharide vaccines against serogroups A
and C, widely used for many years with relative success
in mass immunizations during outbreaks, are efficacious
in older children and in adults, but are much less
immunogenic in children under 5 years old [63]. The
development and use of meningococcal conjugate
vaccine is an alternative to polysaccharide vaccines.
The conjugate vaccines for N. meningitidis are at
Meningitis Prevention and Conjugate Vaccines
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several stages of development and clinical trials.
Besides being more immunogenic than the
polysaccharides, the meningococcal conjugate vaccines
induce “herd immunity” [64]. Most of the efforts toward
the development of meningitis conjugate vaccines first
concentrated on serogroups A and C, at the end of the
1980’s. Studies conducted on children in Gambia and
the United Kingdom showed good immunogenicity and
tolerability for the bivalent conjugate vaccine A-C
[65,66]. Recently, several clinical trials made with
children and teenagers have confirmed the safety,
immunogenicity and capacity to induce
immunological memory of serogroup C
meningococcal vaccine [67-70].
In Africa, an extensive project to wipe out epidemic
meningitis has begun, based upon the utilization of two
vaccines. One of them, a heptavalent product (DTPw,
hepatitis b, Hib, meningococcal conjugate A–C), is to
be used in the expanded program of immunization, and
another product, a monovalent vaccine against
meningococcus A, will be used in the population from
1 to 29 years old [71]. Field trials with both vaccines
are scheduled to begin soon.
The United Kingdom was the first country to include
the conjugate vaccine against serogroup C in a routine
immunization program, in November 1999. After the
use of this vaccine in children and teenagers less than
19 years old, a strong reduction in serogroup C
meningococcal disease was observed [11,72,73].
Recently, Trotter et al. [74] reported that, with a
coverage of 89% vaccination, a reduction of 80% in
the incidence of meningitis by serogroup C was
detected and the number of deaths fell from 78 to 8
during the same time period.
Serogroup B meningococcus is an important
problem in the Americas and Europe due to its high
incidence in these regions, and no effective vaccine is
available to date [75,76]. The development of a
vaccine against serogroup B is a more difficult task.
The similarity between the polysaccharide structure of
the bacterial capsule and carbohydrates naturally found
in humans make this antigen auto-limited or poorly
immunogenic. Furthermore, the use of this
polysaccharide in a vaccine can stimulate the
production of auto-antibodies [77,78]. An alternative
approach to vaccine development is based on outer-
membrane vesicles. Although such vaccines induce an
antibody response and protect against meningococcal
disease, especially among children more than four years
of age [79-82], they do not protect against several
known heterologous strains [83]. On the other hand,
many previously unrecognized proteins were identified
and characterized during the genome sequencing of a
virulent strain, MC58, of meningococcus B [84,85].
Some of these proteins induce bactericidal antibodies
in serum against serogroup B meningococcus. Thus,
there is a new potential vaccine candidate, which should
be safe and capable of promoting strong homologous
and heterologous protection against N. meningitidis
B strains, although it is also likely to promote cross-
protection against other serogroups.
Final Remarks
In this epidemiological scenario post-introduction of
conjugate Hib vaccine into routine immunization
programs, the greatest challenge is to improve the current
surveillance systems. Considering the sharp decrease of
invasive disease as well as the carriage status of Hib,
more sensitive and specific diagnostic tools are essential
to the early detection of the emergence of other H.
influenzae serotypes, especially the non-typeable H.
influenzae and also the S. pneumoniae, which could
occupy the ecological niche left by Hib [86-89]. The
monitoring of possible vaccine failure [90,91], the
reemergence of cases of invasive disease by Hib, despite
adequate levels of vaccine coverage, and the antimicrobial
susceptibility of H. influenzae, including the “non-b”
strains and S. pneumoniae, are also imperative in this
post-vaccine era [92-98].
While waiting for a more effective vaccine against
all meningococcus groups, the best strategy for
meningococcal meningitis prevention is prompt large-
scale mass vaccination during the epidemic period.
Studies carried out in African countries have suggested
that an efficient surveillance system, especially for the
detection of meningococcal meningitis outbreaks, might
guide appropriate control measures, such as a mass
Meningitis Prevention and Conjugate Vaccines
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catch-up vaccination campaign, to timely decrease the
number of cases of the disease [99].
Incorporation of new epidemiological information
might be attained with the use of molecular typing
techniques for the characterization of the invasive
and colonizing serotypes, allowing systematic
evaluations of the Hib vaccine and of the forthcoming
conjugate vaccines of S. pneumoniae and N.
meningitidis, when they become widely available
and implemented.
Acknowledgements
This investigation was sponsored by the Division
of Vaccines and Immunization of the Pan American
Health Organization, World Health Organization, the
Bill and Melinda Gates Children’s Vaccine Program,
the Brazilian Council for Research and Development/
CNPq (Research Grant # 520399/00-5), and the
Secretariat of Health of Goiânia Municipality.
References
1. Hausdorff W. Haemophilus, meningococcus and
pneumococcus: Comparative epidemiologic patterns of
disease. Int J Clin Pract Suppl 2001;(118):2-4.
2. Peltola H. Worldwide Haemophilus influenzae type b
disease at the beginning of the 21st century: Global
analysis of the disease burden 25 years after the use
of the polysaccharide vaccine and a decade after the
advent of conjugates.  Clin Microbiol Rev
2000;13:302-17.
3. Oostenbrink R., Maas M., Moons K.G., Moll H.A. Sequelae
after bacterial meningitis in childhood. Scand J Infect
Dis 2002;34:379-82.
4. Quagliarello V.J., Scheld W.M. Treatment of bacterial
meningitis. N Engl J Med 1997;336:708-16.
5. Ada G.Vaccines and vaccination. N Engl J Med
2001;345:1042-53.
6. Goldblatt D. Recent developments in bacterial conjugate
vaccines. J Med Microbiol 1998;47:563-7.
7. Adams W.G., Deaver K.A., Cochi S.L., et al. Decline of
childhood Haemophilus influenzae type b (Hib) disease
in the Hib vaccine era. JAMA 1993;269:221-6.
8. Levine O.S., Schwartz B., Pierce N., Kane M. Development,
evaluation and implementation of Haemophilus
influenzae type b vaccines for young children in
developing countries: Current status and priority
actions. Pediatr Infect Dis J 1998;17:S95-113.
9. Eskola J., Anttila M. Pneumococcal conjugate vaccines.
Pediatr Infect Dis J 1999;18:543-51.
10. FDA.   Food   and   Drugs   Administration.   First
pneumococcal  vaccine approved for infants and
toddlers. Available: http://www.fda.gov/ bbs/topics/
NEWS/NEW00716.html. Accessed 28 November 2001.
11. Salisbury D. Introduction of a conjugate meningococcal
type C vaccine programme in the UK. J Paediatr Child
Health 2001;37:S34-6.
12. Shinefield H. Pneumococcal conjugate vaccine and
ongoing lessons. Int J Clin Pract Suppl 2001;(118):23-5.
13. World Health Organization. Report of a meeting on
priorities for pneumococcal and Haemophilus
influenzae type b (Hib) vaccine development and
introduction. Geneva, February 2000. Available: http:/
/www.who.int/vaccines-documents/ DocsPDF01/
www530.pdf. Accessed 20 November 2002.
14. Heath P.T. Haemophilus influenzae type b conjugate
vaccines: A review of efficacy data. Pediatr Infect Dis J
1998;17(9 Suppl):S117-22.
15. Dawson K.G., Emerson J.C., Burns J.L. Fifteen years of
experience with bacterial meningitis. Pediatr Infect Dis
J 1999;18:816-22.
16. Di Fabio J.L., de Quadros C. Considerations for combination
vaccine development and use in the developing world.
Clin Infect Dis 2001;33Suppl 4: S340-5.
17. Ruocco G., Curto S., Savio M., et al. Vaccination against
Haemophilus influenzae type b in Uruguay: Experience
and impact. Rev Panam Salud Publica 1999;5:197-9.
18. Takemura N.S., Andrade S.M. Meningite por Haemophilus
influenzae tipo b em cidades do estado do Paraná, Brasil.
J Pediatr (Rio J) 2001;77:387-92.
19. Simões L.L.P., Andrade A.L.S.S., Laval C.A.B.P., et al.
Effectiveness of H. influenzae b conjugate vaccine on
meningitis in Central Brazil. In: International Journal of
Epidemiology. XVI IEA World Congress of
Epidemiology of the International Epidemiology
Association. Oxford, 2002.
20. Freitas H. Meningite por Haemophilus influenzae b no
Distrito Federal. Aspectos epidemiológicos e impacto
após introdução da vacina. In: Dissertação para
obtenção de título de mestre em Saúde Coletiva. 2000.
Universidade de Brasília: Brasília.
21. Ribeiro G.S., Reis J.N., Cordeiro S.M., et al. Prevention of
Haemophilus influenzae type b (Hib) meningitis and
emergence of serotype replacement with type a strains
after introduction of Hib immunization in Brazil. J Infect
Dis 2003;187:109-16.
22. Simões L.L.P. Avaliação da vacina conjugada do
Haemophilus influenzae b: aspectos epidemiológicos
e impacto nas meningites em Goiás. In: Dissertação
para obtenção de título de mestre. 2002. Universidade
Federal de Goiás: Goiânia.
Meningitis Prevention and Conjugate Vaccines
322 BJID 2003; 7 (October)
23. Dickinson F.O., Perez A.E., Galindo M.A., Quintana I.
Impact of vaccination against Haemophilus
influenzae type b in Cuba. Rev Panam Salud Publica
2001;10:169-73.
24. Agudelo C.I., Munoz N., De la Hoz F. Rapid assessment
of the impact of Haemophilus influenzae vaccine
serotype b in Colombia. Public Health Laboratories.
Rev Panam Salud Publica 2000;8:181-4.
25. Landaverde M., Di Fabio J.L., Ruocco G., et al.
Introduction of a conjugate vaccine against Hib in
Chile and Uruguay. Rev Panam Salud Publica
1999;5:200-6.
26. Diaz J.M., Catalan L., Urrutia M.T., et al. Trends of etiology
of acute bacterial meningitis in Chilean children from
1989 to 1998. Impact of the anti-H influenzae type b
vaccine. Rev Med Chil 2001;129:719-26.
27. Barbour M.L., Mayon-White R.T., Coles C., et al. The
impact of conjugate vaccine on carriage of Haemophilus
influenzae type b. J Infect Dis 1995;171:93-8.
28. Adegbola R.A., Mulholland E.K., Secka O., et al.
Vaccination with a Haemophilus influenzae type b
conjugate vaccine reduces oropharyngeal carriage of
H. influenzae type b among Gambian children. J Infect
Dis 1998;177:1758-61.
29. Forleo-Neto E., de Oliveira C.F., Maluf E.M., et al.
Decreased point prevalence of Haemophilus influenzae
type b (Hib) oropharyngeal colonization by mass
immunization of Brazilian children less than 5 years old
with hib polyribosylribitol phosphate polysaccharide-
tetanus toxoid conjugate vaccine in combination with
diphtheria-tetanus toxoids-pertussis vaccine. J Infect
Dis 1999;180:1153-8.
30. Murphy T.V., Pastor P., Medley F., et al. Decreased
Haemophilus colonization in children vaccinated with
Haemophilus influenzae type b conjugate vaccine. J
Pediatr 1993;122:517-23.
31. Takala A.K., Eskola J., Leinonen M., et al. Reduction of
oropharyngeal carriage of Haemophilus influenzae type
b (Hib) in children immunized with an Hib conjugate
vaccine. J Infect Dis 1991;164:982-6.
32. Moulton L.H., Chung S., Croll J., et al. Estimation of the
indirect effect of Haemophilus influenzae type b
conjugate vaccine in an American Indian population.
Int J Epidemiol 2000;29:753-6.




34. World Health Organization. Expert review of a tool for
rapidly assessing Haemophilus influenzae type b (Hib)
disease burden. Geneva, October 2000. Available: http:/
/www.who.int/ vaccines-documents/DocsPDF01/
www604.pdf. Accessed 14 November 2002.
35. Peltola H. Burden of meningitis and other severe bacterial
infections of children in Africa: Implications for
prevention. Clin Infect Dis 2001;32:64-75.
36. Wenger J.D., DiFabio J., Landaverde J.M., et al.
Introduction of Hib conjugate vaccines in the non-
industrialized world: Experience in four ‘newly adopting’
countries. Vaccine 1999;18:736-42.
37. Greenwood B. The epidemiology of pneumococcal
infection in children in the developing world. Philos
Trans R Soc Lond B Biol Sci 1999;354:777-85.
38. Mulholland K. Strategies for the control of pneumococcal
diseases. Vaccine 1999;17Suppl 1:S79-84.
39. Obaro S.K., Monteil M.A., Henderson D.C. The
pneumococcal problem. BMJ 1996;312:1521-5.
40. Hinrichsen J. Six newly recognized types of
Streptococcus pneumoniae. J Clin Microbiol
1995;33:2759-62.
41. Hausdorff W.P., Bryant J., Paradiso P.R., Siber G.R. Which
pneumococcal serogroups cause the most invasive
disease: Implications for conjugate vaccine formulation
and use: I. Clin Infect Dis 2000;30:100-21.
42. Hausdorff W.P., Bryant J., Kloek C., et al. The contribution
of specific pneumococcal serogroups to different
disease manifestations: Implications for conjugate
vaccine formulation and use: II. Clin Infect Dis
2000;30:122-40.
43. Black S., Shinefield H., Fireman B., et al. Efficacy, safety
and immunogenicity of heptavalent pneumococcal
conjugate vaccine in children. Northern California Kaiser
Permanente Vaccine Study Center Group. Pediatr Infect
Dis J 2000;19:187-95.
44. Eskola J., Kilpi T., Palmu A., et al. Efficacy of a
pneumococcal conjugate vaccine against acute otitis
media. N Engl J Med 2001;344:403-9.
45. ANVISA. Agência Nacional de Vigilância Sanitária -
Ministério da Saúde do Brasil. Available: http://
www.anvisa.br. Accessed 25 October 2002.
46. Klugman K.P., Madhi S.A., Huebner R.E., et al. A trial of a
9-valent pneumococcal conjugate vaccine in chiuldren
with and those without HIV infection. N Engl Med
2003;349(14):1341-8.
47. Klugman K.P. Efficacy of pneumococcal conjugate
vaccines and their effect on carriage and antimicrobial
resistance. Lancet Infect Dis 2001;1:85-91.
48. Black S.B., Shinefield H.R., Hansen J., et al. Post licensure
evaluation of the effectiveness of seven valent
pneumococcal conjugate vaccine. Pediatr Infect Dis J
2001;20:1105-7.
49. Dagan R., Sikuler-Cohen M., Zamir O., et al. Effect of a
conjugate pneumococcal vaccine on the occurrence
of respiratory infections and antibiotic use in day-
care center attendees.  Pediatr Infect Dis J
2001;20:951-8.
Meningitis Prevention and Conjugate Vaccines
BJID 2003; 7 (October) 323
50. Dagan R., Melamed R., Muallem M., et al. Reduction of
nasopharyngeal carriage of pneumococci during the
second year of life by a heptavalent conjugate
pneumococcal vaccine. J Infect Dis 1996;174:1271-8.
51. Di Fabio J.L., Castaneda E., Agudelo C.I., et al. Evolution
of Streptococcus pneumoniae serotypes and penicillin
susceptibility in Latin America, Sireva-Vigia Group,
1993 to 1999. PAHO Sireva-Vigia Study Group. Pan
American Health Organization. Pediatr Infect Dis J
2001;20:959-67.
52. Brandileone M.C., Andrade A.L.S.S., DiFabio J.L., et al.
Appropriateness of a pneumococcal conjugate
vaccine in Brazil: Potential impact of age and clinical
diagnosis, with emphasis on meningitis. J Infect Dis
2003;187:1206-12.
53. O’Brien K.L., Bronsdon M.A., Carlone G.M., et al. Effect
of a 7-valent pneumococcal conjugate vaccine on
nasopharyngeal (NP) carriage among Navajo and White
Mountain Apache (N/WMA) infants (abstract 1463).
In: Abstracts of the Society for Pediatric Research,
Baltimore, MD, USA. 2001.
54. O’Brien K.L., Moulton L., Reid R., et al. Invasive disease
efficacy of a 7-valent pneumococcal conjugate vaccine
among Navajo and White Mountain Apache (N/WMA)
children (abstract 1371). In: Abstracts of the Society
for Pediatric Research, Baltimore, MD, USA. 2001.
55. Briles D.E., Hollingshead S., Brooks-Walter A., et al. The
potential to use PspA and other pneumococcal proteins
to elicit protection against pneumococcal infection.
Vaccine 2000;18:1707-11.
56. Brooks-Walter A., Briles D.E., Hollingshead S.K. The
pspC gene of Streptococcus pneumoniae encodes a
polymorphic protein, PspC, which elicits cross-
reactive antibodies to PspA and provides immunity
to pneumococcal bacteremia. Infect Immun.
1999;67:6533-42.
57. McDaniel L.S., Waltman W.D. 2nd, Gray B., Briles D.E. A
protective monoclonal antibody that reacts with a novel
antigen of pneumococcal teichoic acid. Microb Pathog
1987;3:249-60.
58. Briles D.E., Hollingshead S.K., Swiatlo E., et al. PspA and
PspC: Their potential for use as pneumococcal
vaccines. Microb Drug Resist 1997;3:401-8.
59. Hollingshead S.K., Becker R., Briles D.E. Diversity of
PspA: Mosaic genes and evidence for past
recombination in Streptococcus pneumoniae. Infect
Immun 2000;68:5889-900.
60. Briles D.E., Hollingshead S.K., King J., et al. Immunization
of humans with recombinant pneumococcal surface
protein A (rPspA) elicits antibodies that passively
protect mice from fatal infection with Streptococcus
pneumoniae bearing heterologous PspA. J Infect Dis
2000;182:1694-1701.
61. Greenwood B.M. The epidemiology of acute bacterial
meningitis in tropical Africa. In: Williams J.D., Burnie J.
[eds]. Bacterial meningitis. London: Academic Press,
1987: p61-91.
62. Schwartz B., Moore P.S., Broome C.V. Global epidemiology
of meningococcal disease. Clin Microbiol Rev 1989;2
Suppl:S118-24.
63. Gotschlich E.C., Goldschneider I., Artenstein M.S. Human
immunity to the meningococcus. IV: Immunogenicity
of group A and group C meningococcal
polysaccharides in human volunteers. J Exp Med
1969;129:1367-84.
64. Zollinger W.D. In: Levine M.M., Woodrow G.C., Kaper
J.B., et al. (eds). New Generation Vaccines. Deker, New
York, 1997, p. 469.
65. Fairley C.K., Begg N., Borrow R., et al. Conjugate
meningococcal serogroup A and C vaccine:
Reactogenicity and immunogenicity in United Kingdom
infants. J Infect Dis 1996;174:1360-3.
66. Twumasi P.A. Jr., Kumah S., Leach A., et al. A trial of a
group A plus group C meningococcal polysaccharide-
protein conjugate vaccine in African infants. J Infect
Dis 1995;171:632-8.
67. Bramley J.C., Hall T., Finn A., et al. Safety and
immunogenicity of three lots of meningococcal
serogroup C conjugate vaccine administered at 2, 3 and
4 months of age. Vaccine 2001;19:2924-31.
68. English M., MacLennan J.M., Bowen-Morris J.M., et al.
A randomised, double-blind, controlled trial of the
immunogenicity and tolerability of a meningococcal
group C conjugate vaccine in young British infants.
Vaccine 2000;19:1232-8.
69. MacLennan J.M., Shackley F., Heath P.T., et al. Safety,
immunogenicity, and induction of immunologic memory
by a serogroup C meningococcal conjugate vaccine in
infants: A randomized controlled trial. JAMA
2000;283:2795-801.
70. Rennels M.B., Edwards K.M., Keyserling H.L., et al. Safety
and immunogenicity of four doses of Neisseria
meningitidis group C vaccine conjugated to CRM197
in United States infants. Pediatr Infect Dis J
2001;20:153-9.
71. Pan American Health Organization. Meningococcal
conjugate vaccines for África (abstract page 21). In:
Abstracts of Conference on Vaccines, Prevention and
Public Health: A vision for the future. Washington, DC,
USA: PAHO, 2002.
72. Rappuoli R. Conjugates and reverse vaccinology to
eliminate bacterial  meningit is .  Vaccine
2001;19:2319-22.
73. Balmer P., Borrow R., Miller E. Impact of meningococcal C
conjugate vaccine in the UK. J Med Microbiol
2002;51:717-22.
Meningitis Prevention and Conjugate Vaccines
324 BJID 2003; 7 (October)
74. Trotter C.L., Ramsay M.E., Kaczmarski E.B.
Meningococcal serogroup C conjugate vaccination in
England and Wales: Coverage and initial impact of the
campaign. Common Dis Public Health 2002;5:220-5.
75. Morbidity  Mortality  Weekly  Report.  Summary of
notifiable diseases, United States, 1998. Available: http:/
/www.cdc.gov/mmwr/PDF/wk/mm4654.pdf. Accessed
13 January 2003.
76. Scholten R.J., Bijlmer H.A., Poolman J.T., et al.
Meningococcal disease in The Netherlands, 1958-
1990: A steady increase in the incidence since 1982
partially caused by new serotypes and subtypes
of  Neisser ia  meningi t id is .  Cl in  Infect  Dis
1993;16:237-46.
77. Finne J., Bitter-Suermann D., Goridis C., Finne U. An IgG
monoclonal antibody to group B meningococci cross-
reacts with developmentally regulated polysialic acid
units of glycoproteins in neural and extraneural tissues.
J Immunol 1987;138:4402-7.
78. Hayrinen J., Jennings H., Raff H.V., et al. Antibodies
to polysialic acid and its N-propyl derivative:
Binding properties and interaction with human
embryonal brain glycopeptides.  J Infect Dis
1995;171:1481-90.
79. Bjune G., Hoiby E.A., Gronnesby J.K., et al. Effect of outer
membrane vesicle vaccine against group B
meningococcal disease in Norway. Lancet
1991;338:1093-6.
80. Moraes J.C., Perkins B.A., Camargo M.C., et al. Protective
efficacy of a serogroup B meningococcal vaccine in
Sao Paulo, Brazil. Lancet 1992;340:1074-8.
81. Noronha C.P., Struchiner C.J., Halloran M.E. Assessment
of the direct effectiveness of BC meningococcal vaccine
in Rio de Janeiro, Brazil: A case-control study. Int
Epidemiol 1995;24:1050-7.
82. Tappero J.W., Lagos R., Ballesteros A.M., et al.
Immunogenicity of 2 serogroup B outer-membrane
protein meningococcal vaccines: A randomized
controlled trial in Chile. JAMA 1999;281:1520-7.
83. Poolman J.T. Development of a meningococcal vaccine.
Infect Agents Dis 1995;4:13-28.
84. Pizza M., Scarlato V., Masignani V., et al. Identification of
vaccine candidates against serogroup B
meningococcus by whole-genome sequencing. Science
2000;287:1816-20.
85. Tettelin H., Saunders N.J., Heidelberg J., et al. Complete
genome sequence of Neisseria meningitidis serogroup
B strain MC58. Science 2000;287:1809-15.
86. Adderson E.E., Byington C.L., Spencer L., et al. Invasive
serotype a Haemophilus influenzae infections with a
virulence genotype resembling Haemophilus
influenzae type b: Emerging pathogen in the vaccine
era? Pediatrics 2001;108:E18.
87. Cerquetti M., Ciofi degli Atti M.L., Renna G., et al.
Characterization of non-type b Haemophilus influenzae
strains isolated from patients with invasive disease.
The HI Study Group. J Clin Microbiol 2000;38:4649-52.
88. Hausdorff W.P., Siber G., Paradiso P.R. Geographical
differences in invasive pneumococcal disease rates
and serotype frequency in young children. Lancet
2001;357:950-2.
89. Waggoner-Fountain L.A., Hendley J.O., Cody E.J., et al. The
emergence of Haemophilus influenzae types e and f as
significant pathogens. Clin Infect Dis 1995;21:1322-4.
90. Booy R., Heath P.T., Slack M.P., et al. Vaccine failures
after primary immunisation with Haemophilus
influenzae type-b conjugate vaccine without booster.
Lancet 1997;349:1197-202.
91. Breukels M.A., Spanjaard L., Sanders L.A., Rijkers G.T.
Immunological characterization of conjugated
Haemophilus influenzae type b vaccine failure in
infants. Clin Infect Dis 2001;32:1700-5.
92. Andrade A.L.S.S., Brandileone M.C., DiFabio J.L., et al.
Haemophilus influenzae resistance in Latin America:
Systematic review of surveillance data. Microb Drug
Resist 2001;7:375-89.
93. Brandileone M.C., DiFabio J.L., Vieira V.S., et al. Geographic
distribution of penicillin resistance of Streptococcus
pneumoniae in Brazil: Genetic relatedness. Microb Drug
Resist 1998;4:209-17.
94. Galil K., Singleton R., Levine O.S., et al. Reemergence of
invasive Haemophilus influenzae type b disease in a
well-vaccinated population in remote Alaska. J Infect
Dis 1999;179:101-6.
95. Gazagne L., Delmas C., Bingen E., Dabernat H. Molecular
epidemiology of ampicillin-resistant non-beta-
lactamase-producing Haemophilus influenzae. J Clin
Microbiol 1998;36:3629-35.
96. Ko A.I., Reis J.N., Coppola S.J., et al. Clonally related
penicillin-nonsusceptible Streptococcus pneumoniae
serotype 14 from cases of meningitis in Salvador, Brazil.
Clin Infect Dis 2000;30:78-86.
97. Sader H.S., Gales A.C., Granacher T.D., et al. Prevalence of
antimicrobial resistance among respiratory tract isolates in
Latin America: Results from SENTRY antimicrobial
surveillance program (1997-98). Braz J Infect Dis 2000;4:245-
54.
98. Wolf B., Rey L.C., Brisse S., et al. Molecular epidemiology
of penicillin-resistant Streptococcus pneumoniae
colonizing children with community-acquired pneumonia
and children attending day-care centres in Fortaleza,
Brazil. J Antimicrob Chemother 2000;46:757-65.
99. Woods C.W., Armstrong G., Sackey S.O., et al. Emergency
vaccination against epidemic meningitis in Ghana:
Implications for the control of meningococcal disease
in West Africa. Lancet 2000;355:30-3.
Meningitis Prevention and Conjugate Vaccines
